New York Medical Portfolio

KB Exchange Trust is pleased to offer a high-quality, credit-tenant, healthcare investment that is structured as a Delaware Statutory Trust in order to suit 1031 exchange investors. This investment is a two-property portfolio with properties located in large New York metro-markets. The first property is leased to Fresenius Medical Care in Rochester, New York; the second is leased to Walgreens in Paterson, New Jersey, which is part of the New York City metropolitan statistical area (MSA). Investors can expect an initial cash flow of 6.02% from lease income guaranteed by two global healthcare giants: Walgreens Boot Alliance (NASDAQ: WBA) and Fresenius Medical Care (NYSE: FMS), the world’s largest integrated provider of dialysis products and services. This powerful tenant duo has a combined market capitalization in excess of $100 billion with over 200 years of operating history.

Download Investment Summary
Full Name:
E-mail Address:
Phone Number:
Are You In An Exchange?:
Home Kingsbarn Realty Capital
DST Net-Lease Properties
DST Multifamily Net-Lease
Recent Transactions
DST 101
1031 Exchange
Document Vault

Fresenius Medical Care Company Video


About 1031 Exchange Delaware Statutory Trust

About Walgreens Boots Alliance

Walgreens Boots Alliance was created through the merger of Walgreens and Alliance Boots in December 2014, resulting as the largest retail pharmacy, health and daily living destination across the USA and Europe. Walgreens Boots Alliance has a presence in more than 25 countries and employs more than 385,000 people; over half employed in the US. A global leader in pharmacy-led, health and well-being retail, the company has over 13,200 stores in 11 countries; over 8,000 in the US alone.
Walgreens Boots Alliance ranks No. 1 in the Food and Drug Stores industry of Fortune Magazine’s 2017 list of the World’s Most Admired Companies. This is the 24th consecutive year that Walgreens Boots Alliance or its predecessor company, Walgreen Co., have been named to the prestigious list. Walgreens Boots Alliance is ranked on both the Fortune 500® and Global Fortune 500® at 17 and 37, respectively. A $86 billion worldwide company, Walgreens Boots Alliance trades on the NASDAQ under the ticker symbol WBA. Standard and Poor’s ranks Walgreens as an investment grade BBB.

Real Estate Exchange Walgreens Pharmacy Award

About Fresenius Medical Care

Fresenius Medical Care Holdings (Guarantor) is a wholly-owned subsidiary of Fresenius Medical Care AG & Co. KGaA (“Fresenius”), a Fortune Global 500® company. Fresenius is the world’s largest integrated provider of products and services for individuals undergoing dialysis due to chronic kidney failure.
With over 110,000 employees and a network of 3,700 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. Fresenius cares for more than 315,000 patients in their global network and operates more than 37 production sites on all continents, making them the world’s leading provider of dialysis.
A worldwide company with a market cap of approximately $30 billion, Fresenius is traded on both the Frankfurt Stock Exchange (FSE: FME) and the New York Stock Exchange (NYSE: FMS). In January 2015, Standard & Poor’s upgraded the corporate credit rating of Fresenius Medical Care to investment grade with a stable outlook.

Fresenius Medical Care Award


› Equity Offering: $8,200,000

› Minimum Investment: $100,000

› Cap Rate: 5.85%

› Initial Cash Flow: 6.02%


› Located in Densely-Populated New York Metro-Markets

› Long-Term Leases (FMS 14+ Yrs. /WBA 18+ Yrs.)

› Fresenius is Publicly-Traded (NYSE: FMS)

› Walgreens is Publicly-Traded (NASD: WBA)

› Escalating Rental Schedule

› DST Structure Ideal for 1031 Exchanges

Call Us To Discuss This Investment Opportunity: 424.343.9000
Jeff Farnsworth,
Executive Vice-President

This website does not offer to sell, or a solicitation of an offer to buy, securities. Offers can only be made through the Private Placement Memorandum which contains various and important risk disclosures. This web site does not purport to be complete and should be viewed in conjunction with the Private Placement Memorandum. An investment of this sort is speculative and involves a high degree of risk. Projections of future performance contained herein are based on specific assumptions discussed more fully in the Private Placement Memorandum and do not constitute a guaranty of future performance.

DST Interests in any of the properties displayed on this website may be sold only to "accredited investors," as defined in Regulation D under the U.S. Securities Act of 1933, as amended (the "Securities Act"), which, for natural persons, refers to investors who meet certain minimum annual income or net worth thresholds. Offers and sales of DST interests have not and will not be registered under the Securities Act or the laws of any U.S. state or non-U.S. jurisdiction and may be offered only pursuant to an exemption from such registration. Neither the U.S. Securities and Exchange Commission nor any other regulatory authority has passed upon the merits of an investment in the DST Interests, has approved or disapproved of DST Interests or passed upon the accuracy or adequacy of this website and any supplementary materials describing the DST Interests. DST Interests are also not subject to the protections of the Investment Company Act of 1940, including the limitations on self-dealing, affiliated transactions and leverage contained therein. DST Interests are subject to legal restrictions on transfer and resale in accordance with the governing documents of the Trust and applicable securities laws, and investors may be unable to sell or transfer their DST interests. In addition, there is no public market for the DST interests and no such market is expected to develop in the future. Investing in the DST securities involves risk, and investors should be able to bear the loss of their investment.